Samalizumab
Monoclonal antibody
N
Y (what is this?) (verify) Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]
Samalizumab was developed by Alexion Pharmaceuticals.
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
- ^ "Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
